Evidence map›Paper›PMID 25359289›Full record

ArticleEye (London, England)2015

Two-year outcome of an observe-and-plan regimen for neovascular age-related macular degeneration: how to alleviate the clinical burden with maintained functional results.

C Gianniou, A Dirani, W Ferrini, L Marchionno, D Decugis, A Deli, A Ambresin, I Mantel

Erratum issuedAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Eye (London, England), 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed.

  1. Real-world durability of faricimab in treatment-naïve nAMD patients: outcomes of an observe-and-plan regimen.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2026
    Article
  2. Article
  3. Article
  4. Article
  5. [Real-life experiences with Brolucizumab in recalcitrant neovascular age-related macular degeneration].Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft · 2022
    Article
  6. Article
  7. Refractory neovascular age-related macular degeneration: time-dependent changes of central retinal thickness with anti-VEGF treatment.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2021
    Article
  8. Review
  9. Review
  10. Beneficial switch from aflibercept to ranibizumab for the treatment of refractory neovascular age-related macular degeneration.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2020
    Article
  11. Review
  12. Morphologic Criteria of Lesion Activity in Neovascular Age-Related Macular Degeneration: A Consensus Article.Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics · 2018
    Article
  13. Article
  14. Two-year outcome of an observe-and-plan regimen for neovascular age-related macular degeneration treated with Aflibercept.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2017
    Article
  15. Two-year results of a treat-and-extend regimen with aflibercept for polypoidal choroidal vasculopathy.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2017
    Article
  16. Review
  17. Article
  18. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

8 authors.

C GianniouDepartment of Ophthalmology, University of Lausanne, Jules Gonin Eye Hospital, Fondation Asile des aveugles, Lausanne, Switzerland.
A DiraniDepartment of Ophthalmology, University of Lausanne, Jules Gonin Eye Hospital, Fondation Asile des aveugles, Lausanne, Switzerland.
W FerriniDepartment of Ophthalmology, University of Lausanne, Jules Gonin Eye Hospital, Fondation Asile des aveugles, Lausanne, Switzerland.
L MarchionnoDepartment of Ophthalmology, University of Lausanne, Jules Gonin Eye Hospital, Fondation Asile des aveugles, Lausanne, Switzerland.
D DecugisDepartment of Ophthalmology, University of Lausanne, Jules Gonin Eye Hospital, Fondation Asile des aveugles, Lausanne, Switzerland.
A DeliDepartment of Ophthalmology, University of Lausanne, Jules Gonin Eye Hospital, Fondation Asile des aveugles, Lausanne, Switzerland.
A AmbresinDepartment of Ophthalmology, University of Lausanne, Jules Gonin Eye Hospital, Fondation Asile des aveugles, Lausanne, Switzerland.
I MantelDepartment of Ophthalmology, University of Lausanne, Jules Gonin Eye Hospital, Fondation Asile des aveugles, Lausanne, Switzerland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeThe purpose of this study was to report the 2-year outcome of an individually tailored 'observe-and-plan' treatment regimen for neovascular age-related macular degeneration (nAMD), and to investigate its clinical value in terms of functional outcome. This regimen aimed to reduce the clinical burden (visits) by employing individually fixed injection intervals, based on the predictability of an individual's need for retreatment.

methodsThis prospective case series included 104 patients (115 eyes) with nAMD. Following three loading doses of ranibizumab, the disease recurrence interval was determined in monthly observation visits. Retreatment was applied in a series of three injections with individually fixed intervals (2 weeks shorter than the recurrence interval), combined with periodic adjustment of the intervals. The allowed injection intervals in treatment plans ranged from 1 to 3 months. If there was no recurrence at 3 months, the patient could change to monitoring alone.

resultsMean visual acuity (VA) improved by 8.7, 9.7, and 9.2 letters at months 3, 12, and 24, respectively. The mean number of injections was 7.8 and 5.8 during years 1 and 2, respectively, whereas the mean number of ophthalmic examinations was 4.0 and 2.9, respectively. The mean treatment interval (after the loading doses) was 2.0 months during year 1, and 2.2 months during year 2.

conclusionThe observe-and-plan regimen significantly improved and maintained VA over the course of 2 years. This favourable functional outcome was achieved with fewer clinic visits compared with other regimens. Therefore, this observe-and-plan regimen has the potential to alleviate the clinical burden of nAMD treatment.

Indexed as

AgedAngiogenesis InhibitorsAntibodies, Monoclonal, HumanizedDrug Administration ScheduleFemaleFluorescein AngiographyHumansIntraocular PressureIntravitreal InjectionsMaleProspective StudiesRanibizumabRecurrenceRetreatmentTime FactorsTomography, Optical CoherenceAngiogenesis InhibitorsAntibodies, Monoclonal, HumanizedRanibizumabVascular Endothelial Growth Factor AVEGFA protein, human

Identifiers

PMID25359289
PMCPMC4366453

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.